Rani Therapeutics (NASDAQ:RANI) Given Buy Rating at Chardan Capital

Rani Therapeutics (NASDAQ:RANI)‘s stock had its “buy” rating reaffirmed by stock analysts at Chardan Capital in a research note issued on Thursday, Benzinga reports.

A number of other analysts also recently weighed in on RANI. Weiss Ratings restated a “sell (e+)” rating on shares of Rani Therapeutics in a report on Thursday, October 15th. HC Wainwright restated a “buy” rating on shares of Rani Therapeutics in a report on Tuesday, October 6th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Rani Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.33.

Rani Therapeutics Trading Down 3.0%

RANI stock traded down $0.02 on Thursday, hitting $0.59. The company had a trading volume of 402,626 shares, compared to its average volume of 914,543. Rani Therapeutics has a 12-month low of $0.59 and a 12-month high of $2.63. The stock’s 50-day simple moving average is $0.80 and its 200 day simple moving average is $0.83. The stock has a market cap of $81.82 million, a price-to-earnings ratio of -2.19 and a beta of 0.69.

Rani Therapeutics (NASDAQ:RANI) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.01. The business had revenue of $1.71 million for the quarter, compared to analysts’ expectations of $0.93 million. Research analysts forecast that Rani Therapeutics will post -0.17 earnings per share for the current year.

Institutional Investors Weigh In On Rani Therapeutics

Several large investors have recently added to or reduced their stakes in RANI. Squarepoint Ops LLC lifted its position in shares of Rani Therapeutics by 155.5% in the 2nd quarter. Squarepoint Ops LLC now owns 41,902 shares of the company’s stock worth $32,000 after purchasing an additional 25,501 shares during the period. Kestra Private Wealth Services LLC increased its stake in Rani Therapeutics by 4.1% during the 1st quarter. Kestra Private Wealth Services LLC now owns 265,159 shares of the company’s stock valued at $195,000 after purchasing an additional 10,347 shares in the last quarter. Finally, AWM Investment Company Inc. acquired a new position in Rani Therapeutics during the 2nd quarter valued at approximately $5,703,000. 30.19% of the stock is owned by hedge funds and other institutional investors.

Rani Therapeutics Company Profile

Rani Therapeutics Holdings, Inc is a biotechnology company developing oral delivery technologies for biologic medicines that are typically administered by injection. The company’s platform is designed to transport therapeutic molecules through the stomach and release them in the small intestine, where they can be absorbed into the bloodstream.

Its primary technology, the RaniPill capsule, is a robotic oral delivery system intended to deliver biologics, peptides and other large-molecule therapies.